BofA analyst Jason Zemansky lowered the firm’s price target on Werewolf Therapeutics (HOWL) to $7 from $8 and keeps a Buy rating on the shares, citing an updated cash position following the company’s Q3 update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOWL:
- Werewolf Therapeutics presents preclinical data on PREDATOR Platform
- Werewolf Therapeutics Reports Q3 2025 Financial Results
- Werewolf Therapeutics reports Q3 EPS (36c), consensus (38c)
- Werewolf Therapeutics’ WTX-330 Study: A Potential Game-Changer in Oncology
- Werewolf Therapeutics’ Promising Study on WTX-124 in Cancer Treatment